健脾益肾汤联合化疗对晚期非小细胞肺癌中CTCs水平及临床疗效观察

doi:10.3760/cma.j.issn.1007-1245.2023.02.023

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (2): 242-.DOI: 10.3760/cma.j.issn.1007-1245.2023.02.023

健脾益肾汤联合化疗对晚期非小细胞肺癌中CTCs水平及临床疗效观察

龙惠东林云恩梁仕香

广州医科大学附属肿瘤医院肿瘤内科，广州　510095

出版日期:2023-01-15 发布日期:2023-01-30
通讯作者: 林云恩，Email：linyunen@126.com
基金资助:
广东省中医药管理局科研项目（20202111）；广州市中医药和中西医结合科技项目（20202A010014，20212A010015）

Clinical efficacy of Jianpi-Yishen decoction and chemotherapy for patients with advanced non-small cell lung cancer and its effect on CTCs

Long Huidong, Lin Yun'en, Liang Shixiang

Department of Oncology, Tumor Hospital, Guangzhou Medical University, Guangzhou 510095, China

Online:2023-01-15 Published:2023-01-30
Contact: Lin Yun'en, Email: linyunen@126.com
Supported by:
Project of Guangdong Bureau of Traditional Chinese Medicine (20202111); Scientific and Technological Project of Traditional Chinese Medicine and Chinese-Western Medicine (20202A010014 and 20212A010015)

摘要/Abstract

摘要：

目的　探讨健脾益肾汤联合化疗对晚期非小细胞肺癌（NSCLC）患者循环肿瘤细胞（CTCs）水平及临床疗效。方法　选择广州医科大学附属肿瘤医院2019年1月至2020年1月收治的晚期NSCLC患者60例，中医辨证属脾肾两虚证患者为研究对象，其中男33例、女27例，年龄18～75岁。按照是否联合健脾益肾汤治疗分为对照组和中药组，对照组（30例）行TP化疗方案，中药组（30例）行TP化疗方案联合健脾益肾汤治疗。观察两组患者治疗前后CTCs水平，临床症状及生活质量卡氏功能状态评分标准（KPS）评分变化进行比较。统计学方法采用t检验、χ²检验。结果　在CTCs阳性数量方面，治疗后中药组低于对照组［（3.47±1.87）个比（6.90±2.26）个］，差异有统计学意义［t=-6.403，P<0.001）］；在神疲乏力、纳差、腰膝酸软、夜尿、头晕改善方面，治疗后中药组均明显优于对照组（χ²=4.344、9.643、11.915、4.444、5.934，均P<0.05）；在KPS评分方面，治疗后中药组明显优于对照组［（85.83±7.21）分比（80.36±4.86）分］，差异有统计学意义（t=4.626，P=0.036）。结论　健脾益肾汤联合化疗在晚期NSCLC脾肾两虚证患者中能减少CTCs水平，改善患者各项临床症状，从而提高患者生活质量。

关键词:

健脾益肾汤, 非小细胞肺癌, 循环肿瘤细胞, 晚期, KPS评分

Abstract:

Objective　To investigate the clinical efficacy of Jianpi Yishen decoction combined with chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) on and its effect on the level of circulating tumor cells (CTCs). Methods　Sixty patients with advanced NSCLC and Spleen and Kidney difficiency treated in Tumor Hospital, Guangzhou Medical University from January 2019 to January 2021 were selected as the study objects, including 33 males and 27 females; they were 18-75 years old. The patients were divided into a control group and an observation group according to whether they were treated by Jianpi Yishen decoction or not, with 30 cases in each group. The control group was given conventional TP (docetaxel + nedaplatin) chemotherapy; the observation group was given Jianpi Yishen decoction and TP chemotherapy. The levels of CTCs, clinical symptoms, and Karnofsky Performance Status (KPS) of the two groups were observed before and after the treatment. t and χ² tests were applied. Results　After the treatment, the number of CTCs in the observation group was significantly lower than that in the control group [(3.47±1.871) vs. (6.90±2.264)], with a statistical difference (t=-6.403, P<0.001). The symptoms, such as fatigue, anorexia, lumbar debility, nocturia, and dizziness, in the observation group were better than those in the control groups (χ²=4.344, 9.643, 11.915, 4.444, and 5.934; all P<0.05). The KPS score in the observation group was significantly better than that in the control group [(85.83±7.21) vs. (80.36±4.86)], with a statistical difference (t=4.626, P=0.036). Conclusion　Jianpi Yishen decoction combined with chemotherapy for patients with advanced NSCLC can reduce the level of CTCs and improve their clinical symptoms and quality of life.

Key words:

Jianpi Yishen decoction, Advanced non-small cell lung cancer, Circulating tumor cells, KPS score

龙惠东林云恩梁仕香.

健脾益肾汤联合化疗对晚期非小细胞肺癌中CTCs水平及临床疗效观察 [J]. 国际医药卫生导报, 2023, 29(2): 242-.

Long Huidong, Lin Yun'en, Liang Shixiang.

Clinical efficacy of Jianpi-Yishen decoction and chemotherapy for patients with advanced non-small cell lung cancer and its effect on CTCs [J]. International Medicine and Health Guidance News, 2023, 29(2): 242-.

参考文献

[1] Pawlikowska P,Faugeroux V,Oulhen M,et al.Circulating tumor cells (CTCs) for the noninvasive monitoring and personalization of non-small cell lung cancer (NSCLC) therapies[J].J Thorac Dis,2019,11 Suppl 1:S45-S56.DOI:10.21037/jtd.2018.12.80.
[2] Shishido SN,Carlsson A,Nieva J,et al.Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer[J].J Transl Med,2019,17(1):294.DOI:10.1186/s12967-019-2035-8.
[3] 郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:124-129.
[4] Sequist LV,Nagrath S,Toner M,et al.The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients[J].J Thorac Oncol,2009,4(3):281-283.DOI:10.1097/JTO.0b013e3181989565.
[5] Cortés-Hernández LE,Eslami-SZ,Pantel K,et al.Molecular and functional characterization of circulating tumor cells: from discovery to clinical application[J].Clin Chem,2020,66(1):97-104.DOI:10.1373/clinchem.2019.303586.
[6] Zhang C,Wang L,Guan Y,et al.Progress of circulating tumor cells in cancer management[J].Technol Cancer Res Treat,2016,15(3):509-516.DOI:10.1177/1533034615583762.
[7] Cristofanilli M,Budd GT,Ellis MJ,et al.Circulating tumor cells, disease progression, and survival in metastatic breast cancer[J].N Engl J Med,2004,351(8):781-791.DOI:10.1056/NEJMoa040766.
[8] Cohen SJ,Punt CJ,Iannotti N,et al.Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer[J].J Clin Oncol,2008,26(19):3213-3221.DOI:10.1200/JCO.2007.15.8923.
[9] Lindsay CR,Blackhall FH,Carmel A,et al.EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer[J].Eur J Cancer,2019,117:60-68.DOI:10.1016/j.ejca.2019.04.019.
[10] Duan GC,Zhang XP,Wang HE,et al.Circulating tumor cells as a screening and diagnostic marker for early-stage non-small cell lung cancer[J].Onco Targets Ther,2020,13:1931-1939.DOI:10.2147/OTT.S241956.
[11] Bidard FC,Proudhon C,Pierga JY.Circulating tumor cells in breast cancer[J].Mol Oncol,2016,10(3):418-430.DOI:10.1016/j.molonc.2016.01.001.
[12] Krebs MG,Sloane R,Priest L,et al.Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer[J].J Clin Oncol,2011,29(12):1556-1563.DOI:10.1200/JCO.2010.28.7045.
[13] 王燕.肺癌的临床辨证规律探讨[J].国际医药卫生导报,2007,13(9):112-113.DOI:10.3760/cma.j.issn.1007-1245. 2007.09.046.
[14] 王炜明,赵东娇.西洋参中有效成分及其抗肿瘤关系的研究进展[J].中国民族民间医药,2013,22(10):43-44.DOI:10.3969/j.issn.1007-8517.2013.10.028.
[15] 周丹,王杏娥,曾祥平.黄芪皂苷、多糖及黄酮在抗细胞凋亡方面的研究进展[J].现代生物医学进展,2011,11(S1):4687-4689,4724.DOI:10.13241/j.cnki.pmb.2011.s1.016.
[16] 张静.黄芪甲苷对大鼠肠道缺血再灌注损伤的保护作用[J].国际医药卫生导报,2022,28(17):2396-2399.DOI:10.3760/cma.j.issn.1007-1245.2022.17.006.
[17] 蒋艳,姜孝新.枸杞多糖对肝癌Hca-F 荷瘤小鼠的抗肿瘤作用及其机制[J].肿瘤药学,2011,1(4):391-394.DOI:10.3969/j.issn.2095-1264.2011.04.020.
[18] 邹品文,赵春景,李攀,等.山茱萸多糖的抗肿瘤作用及其免疫机制[J].中国医院药学杂志,2012,32(1):20-22.DOI:10.13286/j.cnki.chinhosppharmacyj.2012.01.004.
[19] 曾惠玉.白术不同化学成分的药理作用研究[J].临床合理用药杂志,2018,11(29):177-178.DOI:10.15887/j.cnki. 13-1389/r.2018.29.118.
[20] 蔡宇,杨燕霞,梁少玲,等.补骨脂素对乳腺癌多药耐药细胞株Bcl-2基因蛋白表达的影响[J].中药材,2004,27(11):855-856.DOI:10.3321/j.issn:1001-4454.2004.11.028.

健脾益肾汤联合化疗对晚期非小细胞肺癌中CTCs水平及临床疗效观察

Clinical efficacy of Jianpi-Yishen decoction and chemotherapy for patients with advanced non-small cell lung cancer and its effect on CTCs

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics